| Acne |
No |
| Active substance |
Pioglitazone |
| Also known as |
Pioglitazone hydrochloride |
| Aromatization |
No |
| Blood pressure |
Could potentially cause fluid retention which might increase blood pressure |
| Chemical name |
5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione |
| Dosage (medical) |
Typically 15-45 mg per day |
| Dosage (sports) |
Not applicable |
| Effects |
Lowers blood glucose, increases insulin sensitivity |
| Formula |
C19H20N2O3S |
| Half-life |
3-7 hours |
| HBR |
No |
| Hepatotoxicity |
No |
| Lab Test |
Monitoring blood glucose and liver function tests |
| Main action |
Antidiabetic, insulin sensitizer |
| Side effects |
Weight gain, edema, heart failure, increased risk of bladder cancer, bone fractures |
| Storage conditions |
Store at room temperature, protect from moisture and light |
| Substance class |
Thiazolidinedione |
| Trade name |
Actos |
| Use in sports |
Not typically used in sports |
| WAREHOUSE |
International Warehouse 2 |
| Water Retention |
No |
| Manufacturer |
Takeda |
